EUVIMEDEUVIMED entdecken
Crossref

Development of a novel Fc fusion protein dual glucagon‐like peptide‐1 and gastric inhibitory polypeptide receptor agonists

Peng Jiang, Ningyuan Sun, Wen Yang, Lin Xiao, Linjun Zhou, Baohua Gu, Yong Li, Lijia Li, Jing Li, Xiaoping Li, Wenjia Li, Linfeng Guo iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Peng Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dongguan HEC Biopharmaceutical R&D Co., Ltd., Dongguan, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To develop and investigate an imbalanced dual gastric inhibitory polypeptide receptor (GIPR)/glucagon‐like peptide‐1 receptor (GLP‐1 R) agonist with Fc fusion protein structure.

Methods

We designed and constructed an Fc fusion protein that is a dual agonist (HEC‐CG115) with an empirically optimized potency ratio for GLP‐1R and GIPR. The long‐term effects of HEC‐CG115 on body weight and glycaemic control were evaluated in diet‐induced obese mice and diabetic db/db mice. Repeat dose toxicity assays were performed to investigate the safety profile of HEC‐CG115 in Sprague‐Dawley rats.

Results

HEC‐CG115 displayed high potency for GIPR and relatively low potency for GLP‐1R, and we labelled it ‘imbalanced’. In animal models, HEC‐CG115 (3 nmol/kg) led to more weight loss than semaglutide at a higher dose (10 nmol/kg) in diet‐induced obese model mice. HEC‐CG115 (one dose every 3 days) reduced fasting blood glucose and glycated haemoglobin levels similar to those after semaglutide (once daily) at the same dose. In a 4‐week subcutaneous toxicity study conducted to assess the biosafety of HEC‐CG115, the no observed adverse effect level was determined to be 3 mg/kg.

Conclusion

HEC‐CG115 is a novel Fc fusion protein with imbalanced dual agonism that shows superior weight loss, glycaemic control and metabolic improvement in animal models, and has an optimal safety profile according to a repeat‐dose toxicity study. Therefore, the use of HEC‐CG115 appears to be safe and effective for the treatment of obesity and type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsAnimalsMiceRatsGastric Inhibitory PolypeptideRats, Sprague-DawleyReceptors, G-Protein-CoupledWeight LossReceptors, Gastrointestinal Hormone

Stichwörter der Autor:innen

GIPGLP-1glycaemic controlobesity therapyweight control

Substanzen

Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1Receptors, G-Protein-CoupledGlucagon-Like Peptide-1 Receptor Agonistsgastric inhibitory polypeptide receptorReceptors, Gastrointestinal Hormone

Autor:innen und Institutionen

  • Dongguan HEC Biopharmaceutical R&D Co., Ltd., Dongguan, China.
  • Sunshine Lake Pharma Co., Ltd., Dongguan, China.

ORCID-Profile: Linfeng Guo

Zitieren

APA

Jiang, P., Sun, N., Yang, W., Xiao, L., Zhou, L., Gu, B., Li, Y., Li, L., Li, J., Li, X., Li, W., & Guo, L. (2023). Development of a novel Fc fusion protein dual glucagon‐like peptide‐1 and gastric inhibitory polypeptide receptor agonists. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15235

Vancouver

Jiang P, Sun N, Yang W, Xiao L, Zhou L, Gu B, et al. Development of a novel Fc fusion protein dual glucagon‐like peptide‐1 and gastric inhibitory polypeptide receptor agonists. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15235

BibTeX
@article{Jiang2023,
  author = {Jiang, Peng and Sun, Ningyuan and Yang, Wen and Xiao, Lin and Zhou, Linjun and Gu, Baohua and Li, Yong and Li, Lijia and Li, Jing and Li, Xiaoping and Li, Wenjia and Guo, Linfeng},
  title = {Development of a novel Fc fusion protein dual glucagon‐like peptide‐1 and gastric inhibitory polypeptide receptor agonists},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15235}
}
Kostenlos starten →